Diagnosis of Familial Dysbetalipoproteinemia Based on the Lipid Abnormalities Driven by APOE2/E2 Genotype
Clinical Chemistry · 2023
DOI: 10.1093/clinchem/hvac213 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Chemistry, 2023. Verfasst von Ana M Bea und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Miguel Servet, IIS Aragn, CIBERCV, Zaragoza, Spain. Hauptthemen laut MEDLINE: Hyperlipoproteinemia Type III, Hyperlipidemias. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Background
Familial dysbetalipoproteinemia (FDBL) is a monogenic disease due to variants in APOE with a highly variable phenotype. Current diagnostic lipid-based methods have important limitations. The objective is twofold: to define characteristics of dysbetalipoproteinemia (DBL) based on the analysis of APOE in patients from a lipid unit and in a sample from the general population, and to propose a screening algorithm for FDBL.
Methods
Lipids and APOE genotype from consecutive unrelated subjects from Miguel Servet University Hospital (MSUH) (n 3603), subjects from the general population participants of the Aragon Workers Health Study (AWHS) (n 4981), and selected subjects from external lipid units (Ext) (n 390) were used to define DBL criteria and to train and validate a screening tool.
Results
Thirty-five subjects from MSUH, 21 subjects from AWHS, and 31 subjects from Ext were APOE2/2 homozygous. The combination of non high-density lipoprotein cholesterol (non-HDLc)/apoB 1.7 plus triglycerides/apoB 1.35, in mg/dL (non-HDLc [mmol/L]/apolipoprotein B (apoB) [g/L] 4.4 and triglycerides [mmol/L]/apoB [g/L] 3.5), provided the best diagnostic performance for the identification of subjects with hyperlipidemia and APOE2/2 genotype (sensitivity 100 in the 3 cohorts, and specificity 92.8 [MSUH], 80.9 [AWHS], and 77.6 [Ext]). This improves the performance of previous algorithms. Similar sensitivity and specificity were observed in APOE2/2 subjects receiving lipid-lowering drugs.
Conclusions
The combination of non-HDLc/apoB and triglycerides/apoB ratios is a valuable tool to diagnose DBL in patients with hyperlipidemia with or without lipid-lowering drugs. FDBL diagnosis requires DBL and the presence of a compatible APOE genotype. Most adult APOE2/2 subjects express DBL, making FDBL as common as familial hypercholesterolemia in the population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hospital Universitario Miguel Servet, IIS Aragn, CIBERCV, Zaragoza, Spain.
- Molecular Research Laboratory, Instituto Aragones de Ciencias de la Salud (IACS), Zaragoza, Spain.
- Departamento de Medicina, Psiquiatra y Dermatologa, Universidad de Zaragoza, Zaragoza, Spain.
- Fundacin Biofisika Bizkaia, Leioa, Spain.
- Biofisika Institute (UPV/EHU, CSIC), Leioa, Spain.
- Department of Biochemistry and Molecular Biology, Universidad del Pas Vasco UPV/EHU, Bilbao, Spain.
ORCID-Profile: Xavier Pint, Fernando Civeira
Zitieren
APA
Bea, A. M., Cenarro, A., Marco-Bened, V., Laclaustra, M., Martn, C., Ibarretxe, D., Pint, X., Arrobas, T., Vials, C., Civeira, F., & Olmos, S. (2023). Diagnosis of Familial Dysbetalipoproteinemia Based on the Lipid Abnormalities Driven by APOE2/E2 Genotype. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvac213
Vancouver
Bea AM, Cenarro A, Marco-Bened V, Laclaustra M, Martn C, Ibarretxe D, et al. Diagnosis of Familial Dysbetalipoproteinemia Based on the Lipid Abnormalities Driven by APOE2/E2 Genotype. Clinical Chemistry. 2023. doi:10.1093/clinchem/hvac213
BibTeX
@article{Bea2023,
author = {Bea, Ana M and Cenarro, Ana and Marco-Bened, Victoria and Laclaustra, Martn and Martn, Csar and Ibarretxe, Daiana and Pint, Xavier and Arrobas, Teresa and Vials, Clara and Civeira, Fernando and Olmos, Salvador},
title = {Diagnosis of Familial Dysbetalipoproteinemia Based on the Lipid Abnormalities Driven by APOE2/E2 Genotype},
journal = {Clinical Chemistry},
year = {2023},
doi = {10.1093/clinchem/hvac213}
}
EUVIMED